title: Comparison of oral erythromycin formulations in the horse using pharmacokinetic profiles.
abstract: The pharmacokinetic properties of four erythromycin formulations were compared in six adult horses after administration of single and multiple oral doses. Formulations of erythromycin administered were estolate and phosphate given 37.5 mg/kg every 12 h and 25 mg/kg every 8 h, and stearate and ethylsuccinate given 25 mg/kg every 8 h. Areas under the curve (AUC) and maximum plasma erythromycin concentrations (Cmax) were equal or greater (P > or = 0.05) following administration of erythromycin phosphate and stearate compared with those values following administration of erythromycin estolate or ethylsuccinate. In comparing an 8 h vs. a 12 h dosage interval for multiple doses of erythromycin phosphate or estolate, there were no significant differences observed in AUC(24-28 h), peak-trough plasma concentrations or duration that plasma concentrations exceeded the minimal inhibitory concentration (MIC) for Rhodococcus equi. Comparisons of pharmacokinetic parameters between single and multiple doses were made for each formulation. Differences in Cmax, tmax, or t1/2 beta between single and multiple doses were demonstrated for erythromycin ethylsuccinate and estolate. Based on equivalent plasma antibiotic concentrations, erythromycin phosphate or stearate could be substituted for estolate in the treatment of Rhodococcus equi pneumonia. Furthermore, there was no advantage of an 8-h interval, compared with an interval of 12 h.
authors.affiliation: Department of Physiological Sciences, College of Veterinary Medicine, Oklahoma State University, Stillwater 74078.
authors.forename: P J
authors.initials: PJ
authors.lastname: Ewing
authors.forename: G
authors.initials: G
authors.lastname: Burrows
authors.forename: C
authors.initials: C
authors.lastname: MacAllister
authors.forename: C
authors.initials: C
authors.lastname: Clarke
mesh_terms: D000193:Actinomycetales Infections / Q000188:drug therapy / Q000662:veterinary; D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D004917:Erythromycin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D005569:Formularies as Topic; D006207:Half-Life; D006734:Horse Diseases / Q000188:drug therapy / Q000382:microbiology; D006736:Horses / Q000378:metabolism*; D008297:Male; D011014:Pneumonia / Q000188:drug therapy / Q000662:veterinary; D016929:Rhodococcus equi / Q000187:drug effects
chemical_list: D004917:Erythromycin